Canagliflozin Patent Expiration
Canagliflozin is used for the treatment of type 2 diabetes mellitus and reduction of cardiovascular and kidney-related risks. It was first introduced by Janssen Pharmaceuticals Inc
Canagliflozin Patents
Given below is the list of patents protecting Canagliflozin, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Invokana |
US10617668 (Pediatric) | Pharmaceutical formulations | Nov 11, 2031 | Janssen Pharms |
| Invokana | US10617668 | Pharmaceutical formulations | May 11, 2031 | Janssen Pharms |
| Invokana |
US7943582 (Pediatric) | Crystalline form of 1-(β-D-glucopyransoyl)-4-methyl-3-[5-(4-fluorophenyl)-2- thienylmethyl]benzene hemihydrate | Aug 26, 2029 | Janssen Pharms |
| Invokana | US7943582 | Crystalline form of 1-(β-D-glucopyransoyl)-4-methyl-3-[5-(4-fluorophenyl)-2- thienylmethyl]benzene hemihydrate | Feb 26, 2029 | Janssen Pharms |
| Invokana |
US8513202 (Pediatric) | Crystalline form of 1-(beta-D-glucopyranosyl)-4-methyl-3-[5-(4-fluorophenyl)-2-thienylmethyl]benzene hemihydrate | Jun 03, 2028 | Janssen Pharms |
| Invokana |
US7943788 (Pediatric) | Glucopyranoside compound | Jan 14, 2028 | Janssen Pharms |
| Invokana | US8513202 | Crystalline form of 1-(β-D-glucopyranosyl)-4-methyl-3-[5-(4-fluorophenyl)-2-thienylmethyl]benzene hemihydrate | Dec 03, 2027 | Janssen Pharms |
| Invokana | US7943788 | Glucopyranoside compound | Jul 14, 2027 | Janssen Pharms |
| Invokana |
US8222219 (Pediatric) | Glucopyranoside compound |
Oct 11, 2025
(Expired) | Janssen Pharms |
| Invokana | US8222219 | Glucopyranoside compound |
Apr 11, 2025
(Expired) | Janssen Pharms |
Canagliflozin's Family Patents
Explore Our Curated Drug Screens
Clinical Trials
Recent Clinical Trials on Canagliflozin:
Sometimes companies keep conducting clinical trials even after the drug's approval to discover new formulations, methods of use, or new treatment indications, so they could file for additional patents or receive regulatory exclusivity extensions, such as pediatric exclusivity, potentially delaying generic competition. Based on these recent clinical trials, generic companies need to consider the potential for new intellectual property or regulatory hurdles. These strategic moves by the drug owner might delay generic substitution or lead to additional sales of the brand drug, even after patent expiry.
| Title | Lead Sponsor | Collaborators | Status | Phases |
|---|---|---|---|---|
 | ||||
| Safety and Efficacy of Canagliflozin in Patients With Locally Advanced or Advanced Solid Cancer | West China Hospital | NA |
RECRUITING
(Sep 1, 2026)
| PHASE1 |
| Renal Mechanism of SGLT2 Inhibition | University of Colorado, Denver | NA |
ACTIVE NOT RECRUITING
(May 1, 2026)
| PHASE2 |
| Empagliflozin in ESKD - A Feasibility Study | University of Mississippi Medical Center | NA |
ACTIVE NOT RECRUITING
(May 1, 2026)
| PHASE1, PHASE2 |
| Canagliflozin Targeting Vascular Inflammation | Ottawa Heart Institute Research Corporation | NA |
RECRUITING
(Apr 1, 2026)
| PHASE2, PHASE3 |
| Effect of Canagliflozin on Ultrafiltration & Fibrosis in Patients on Peritoneal Dialysis | McGill University Health Centre/Research Institute of the McGill University Health Centre | NA |
RECRUITING
(Mar 1, 2026)
| PHASE2 |